Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:ACLXNASDAQ:MRUSNASDAQ:NRIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.95+0.7%$18.68$13.40▼$25.23$3.84B0.651.94 million shs2.41 million shsACLXArcellx$63.82+1.5%$62.53$47.86▼$107.37$3.52B0.28603,145 shs409,507 shsMRUSMerus$52.59-0.9%$47.60$33.19▼$62.98$3.64B1.04752,845 shs1.96 million shsNRIXNurix Therapeutics$11.62+2.0%$10.80$8.18▼$29.56$885.86M2.15859,866 shs491,613 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+5.57%+5.81%+36.69%+54.34%ACLXArcellx0.00%-4.04%+5.42%-7.95%+18.60%MRUSMerus0.00%-5.06%+19.50%+11.33%-3.04%NRIXNurix Therapeutics0.00%-2.84%+14.60%-10.55%-36.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.6838 of 5 stars3.31.00.00.02.64.22.5ACLXArcellx2.4792 of 5 stars3.53.00.00.02.02.50.0MRUSMerus3.4155 of 5 stars4.63.00.00.03.31.70.0NRIXNurix Therapeutics1.2917 of 5 stars3.41.00.00.01.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.69Moderate Buy$26.7916.71% UpsideACLXArcellx 3.07Buy$111.2374.29% UpsideMRUSMerus 3.14Buy$84.6460.94% UpsideNRIXNurix Therapeutics 2.83Moderate Buy$30.18159.69% UpsideCurrent Analyst Ratings BreakdownLatest NRIX, MRUS, ACAD, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ACLXArcellxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$110.006/16/2025ACLXArcellxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.006/6/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $30.006/5/2025ACADACADIA PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/5/2025ACADACADIA PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Hold$18.00 ➝ $23.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/21/2025ACADACADIA PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.00 ➝ $35.005/20/2025ACADACADIA PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $24.005/19/2025ACADACADIA PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $31.005/19/2025ACADACADIA PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.005/19/2025ACADACADIA PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.00 ➝ $26.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M4.01$0.70 per share32.56$4.40 per share5.22ACLXArcellx$76.81M45.79N/AN/A$8.41 per share7.59MRUSMerus$36.13M100.74N/AN/A$9.46 per share5.56NRIXNurix Therapeutics$54.55M16.24N/AN/A$7.44 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3716.7530.204.9122.97%17.46%10.75%8/5/2025 (Estimated)ACLXArcellx-$107.35M-$2.99N/AN/AN/A-211.46%-35.27%-22.73%8/14/2025 (Estimated)MRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.80N/AN/AN/A-369.40%-47.49%-36.10%7/10/2025 (Estimated)Latest NRIX, MRUS, ACAD, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/10/2025Q2 2025NRIXNurix Therapeutics-$0.73N/AN/AN/A$16.26 millionN/A5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 million4/8/2025Q1 2025NRIXNurix Therapeutics-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AACLXArcellxN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.882.80ACLXArcellxN/A4.934.93MRUSMerusN/A5.865.86NRIXNurix TherapeuticsN/A6.266.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ACLXArcellx96.03%MRUSMerus96.14%NRIXNurix TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%ACLXArcellx8.35%MRUSMerus4.57%NRIXNurix Therapeutics7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million123.01 millionOptionableACLXArcellx8055.11 million50.51 millionOptionableMRUSMerus3769.21 million66.05 millionOptionableNRIXNurix Therapeutics30076.24 million70.60 millionOptionableNRIX, MRUS, ACAD, and ACLX HeadlinesRecent News About These CompaniesAnalysts Conflicted on These Healthcare Names: Align Tech (ALGN), Nurix Therapeutics (NRIX) and Thermo Fisher (TMO)June 19 at 12:50 AM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Telix Pharmaceuticals (OtherTLPPF)June 14, 2025 | theglobeandmail.comNurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | globenewswire.comNurix drops after new early-stage trial data for lead assetJune 13, 2025 | msn.comNurix Therapeutics (NASDAQ:NRIX) Shares Down 5.9% - What's Next?June 12, 2025 | marketbeat.comNurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)June 12, 2025 | globenewswire.comTruist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)June 11, 2025 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Dexcom (DXCM) and Immunovant (IMVT)June 10, 2025 | theglobeandmail.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 10, 2025 | marketbeat.comNurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European ...June 7, 2025 | manilatimes.netNurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)June 6, 2025 | globenewswire.comNurix Therapeutics (NASDAQ:NRIX) Shares Gap Up - Time to Buy?June 3, 2025 | marketbeat.comNurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?June 3, 2025 | zacks.comSanofi Exercises License Extension Option to Nurix’s STAT6 ProgramJune 3, 2025 | finance.yahoo.comSanofi Exercises License Extension Option to Nurix's STAT6 ProgramJune 2, 2025 | globenewswire.comTwo Sigma Investments LP Purchases 84,375 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)June 1, 2025 | marketbeat.comNuveen Asset Management LLC Trims Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 31, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Trading 3.9% Higher - Should You Buy?May 30, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Position Boosted by Wellington Management Group LLPMay 30, 2025 | marketbeat.comNurix Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comMillennium Management LLC Grows Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRIX, MRUS, ACAD, and ACLX Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$22.95 +0.15 (+0.66%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$23.18 +0.23 (+0.98%) As of 08:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Arcellx NASDAQ:ACLX$63.82 +0.94 (+1.49%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$64.00 +0.18 (+0.28%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Merus NASDAQ:MRUS$52.59 -0.49 (-0.92%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$52.54 -0.06 (-0.10%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Nurix Therapeutics NASDAQ:NRIX$11.62 +0.23 (+2.02%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$11.62 +0.01 (+0.04%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
